May 2022

The best way to

beat cancer is to
catch it early.
Advancing pre-cancer and cancer screening
with CDA technology and multi-disciplinary
expertise.

NASDAQ: ANPC
Disclaimer
The information in this presentation is provided to you by AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” “we” or the “Company”) solely for informational purpose and does not
constitute an offer to buy or sell or solicitation of an offer to buy or sell, any securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor
may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever in the United States or anywhere else. Specifically, this
presentation does not constitute a “prospectus” within the meaning of the U.S. Securities Act of 1933, as amended (the “Securities Act”). No securities of the Company may be
offered or sold in the United States without registration with the U.S. Securities and Exchange Commission (the “SEC”) unless pursuant to an available exemption from the
registration requirement of the Securities Act. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the
risks and special considerations involved with an investment in the securities of the Company. No representation or warranty express or implied is made as to, and no reliance
should be placed on, the fairness, accuracy, completeness or correctness of any opinion contained herein. The information contained in this presentation should be considered in
the context of the circumstances prevailing at the time and will not be updated to reflect material developments that may occur after the date of the presentation.
This presentation is being communicated only to persons who have professional experience in matters relating to investments and to persons to whom it may be lawful to
communicate it. This presentation does not constitute legal, regulatory, accounting or tax advice to you. This presentation does not constitute and should not be considered as any
form of financial opinion or recommendation by the Company or any other party. Neither the Company nor any of its affiliates, officers, directors or advisors shall have any liability
whatsoever (in negligence or otherwise) for any loss arising from any use of this presentation or its contents or otherwise arising in connection with this presentation.
This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company’s future
financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “projects,” “intends,” “potential,” “target,” “aim,” “predict,” “outlook,” “seek,” “goal” “objective,” “assume,” “contemplate,” “continue,” “positioned,” “forecast,”
“likely,” “may,” “could," “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking
statements.

2
Disclaimer (Continued)
These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also
involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any
forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of the Company’s business model and
growth strategies; trends and competition in the cancer screening and detection market; its expectations regarding demand for and market acceptance of its cancer screening and
detection tests and its ability to expand its customer base; its ability to obtain and maintain intellectual property protections for its CDA technology and its continued research and
development to keep pace with technology developments; its ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have its
laboratories certified or accredited by authorities including the CLIA; its future business development, financial condition and results of operations and its ability to obtain
financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; its ability to hire and maintain key
personnel; its relationship with its major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic
conditions and financial markets and the Company’s business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel
restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. Additionally, all forward-looking statements are subject to
the “Risk Factors” detailed from time to time in the Company’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission.
Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak
only as of the date of this presentation and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements
for any reason.

Certain data in this presentation was obtained from various external data sources, and the Company has not verified such data with independent sources. Accordingly, the
Company makes no representations as to the accuracy or completeness of such data, and such data involves risks and uncertainties and is subject to change based on various
factors.

THE INFORMATION CONTAINED IN THIS DOCUMENT MAY NOT BE FORWARDED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON (WHETHER
WITHIN OR OUTSIDE YOUR ORGANIZATION/ FIRM) FOR ANY PURPOSE AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. ANY FORWARDING, PUBLICATION,
DISTRIBUTION OR REPRODUCTION OF THIS DOCUMENT IN WHOLE OR IN PART IS UNAUTHORIZED.

By accessing this presentation, you are agreeing to be bound by the foregoing limitations.

3
AnPac Bio (NASDAQ: ANPC) Overview
AnPac Bio is a biotechnology company focused on early
cancer and pre-cancer screening and detection with
operations in China and the United States.
Solution:
AnPac detects the risk of pre-cancer diseases and cancer at
early stages with multiple advantages (lower cost, close to 30
types of cancer, high sensitivity and specificity)
Technology:
155 issued patents globally*
Financial Summary:
Revenue from cancer risk assessment tests since 2015 in Asia

4
*As of March 31, 2022
Key Facts

Company

2
Founded in clinical laboratories

2010
in China*
NASDAQ: ANPC
1
clinical laboratories
in US*

Technology

patent applications

258,238 260 globally (including

142 issued)*

***Accumulated commercial
CDA-based tests
*As of March 31, 2022
**Frost & Sullivan – Among companies
155 patents issued*

According to our public searches, some of our patents, including our newly issued
offering next generation early cancer
screening and detection technologies U.S. patents, have been cited by patent examiners and third parties (including a
***As of March 31, 2022 number of well-known global corporations and Fortune 50 companies). 5
China Progress* and U.S. Penetration** Roadmap and Progress

*Positive results from a ** Lab in Pennsylvania

multi-Year lung cancer obtained CLIA
prognosis and registration in 2020
recurrence clinical study

** Awarded the Minority ** Current Publications ** We plan to market

Health Products & & Presentation (Breast our CDA-based test as a
Services Firm of the Year Cancer symposium, laboratory-developed
by the U.S. Department ASCO, etc.) in test, or LDT in the future
of Commerce in 2018 2015-2019

6
Significant Cancer Screening Volume and Database
The number of total samples
- ranked 1st in the world
 • Born to a medical doctor’s family. Attended medical
Executive Profiles school. Later switched major to physics

• Worked for three U.S. Fortune 500 companies

• First or principal Inventor of over 300 patent applications,

spanning semiconductor, materials and life science

• Received his doctoral degree in physics from the

Dr. Chris Yu
Pennsylvania State University
CEO & Co-founder
• Proven history of developing innovative products
Dr. Yu has enjoyed a successful career as
an innovator in life sciences, materials • His master and doctoral dissertations involved innovative
and integrated circuits, particularly using detection techniques
integrated circuit devices for cancer
detection • Contributed to the founding or success of three publically
traded high tech companies as a founding executive or
co-founder 8
Introduction of Dr. Chris Yu’s Successful Entrepreneurial
Achievements

• Cabot Microelectronics • Anji Microelectronics • Anpac (Stock Code:

(stock code: CCMP) Listed Technology (Stock Code:
on Nasdaq in 2000 688019.SH)
• As the main founding team • The first batch of listings on
member, R&D director, R&D the Science and Technology
vice president Innovation Board in 2019
• As a co-founder
ANPC) Listed on NASDAQ
in 2020
• Cancer screening and
detection company with
its main business in China
listed in the United States
• As the co-founder
Executive Profiles

Dr. Herbert Yu
Co-founder/Chief
Medical Officer
• Renowned expert in a molecular epidemiology, with
training in medicine, epidemiology, and clinical
biochemistry
• Professor & Program Director at University of Hawaii &
Adjunct Professor at Yale University
• Received master of science in epidemiology and PhD in
clinical biochemistry from University of Toronto in 1990
and 1996, respectively
Xuedong Du
Vice President of R&D
• Master of Electronics and Communications
Engineering at Fudan University
• Worked for a manufacturing company (a subsidiary
of a U.S. listed company), served as its engineer,
senior engineer, chief engineer, and manager
• More than 100 Chinese and inventional patents, of
which 81 have been authorized
• Approximately 20 papers have been published in
professional journals and academic conferences in
the world
10
Executive Profiles
Weidong Dai
China General
Manager
• Served as chief scientific officer, director or chairman
of a number of biomedical or other companies,
general partner of an investment management
company
• Received his master’s degree in medicine from
Sun Yat-San University of Medicine, and an
Advanced Certificate of the EMBA CEO Program
from Fudan University, School of Economics
Jinqiu Tang
Chief Financial
Officer
• Served as a global internal auditor at Natuzzi S.p.A
• Worked at Beijing Dongshen CPA and Shanghai De’an
CPAs providing external audit, finance, and tax advisory
services across different industries and sectors
• Received bachelor’s degree in accounting from Charles
Sturt University in Australia, MBA from Charles Sturt
University in Australia
11
Geographic Overview

86 Employees*
• AnPac Bio’s 86 employees
comprise creative and innovative
scientists, researchers, engineers,
and business professionals in China
and the U.S.

• Educated at
internationally-acclaimed,
universities and educational
institutions; and recruited from
Fortune 500, NYSE- and
NASDAQ-listed.

*As of December 31, 2020 12

Patent Detail*

Patent

260
applications filed
globally
(including 142
issued)

~20 Countries and regions

155 Patents have been

issued

According to our public searches, some of our patents, including our newly issued U.S. patents, have been cited
by patent examiners and third parties (including a number of well-known global corporations and Fortune 50
companies).
*As of March 31, 2022
13
Anpac Bio Product Pipeline
Regulatory approval application efforts
• LDT certification application (US) Cancer
Differentiation
• Class III medical device Analysis Technology Genomics
application (China) Test
(CDA)

Anpac has developed a number of new products

ADME APCS
Immunology CDA+ct-DNA
Test
COVID-19
Antibody test*

*AnPac San Jose lab is qualified to perform and test by Roche 14

Cancer Differentiation Analysis (CDA)
Multiple High sensitivity
Integrated sensor system
cancer types and specificity
Blood samples • up to 26 cancer types

Biophysical signals

Multiple biological levels Significant Multiple Research

information (protein, cellulardatabase~258,238
and molecular levels) • Accumulated commercial
CDA-based tests, as of
March 31, 2022
studies
• Research studies on CDA
technology with third-party
hospitals, medical
institutions, and universities
in China

15
Biophysical Properties of Blood and Cancer
The CDA technology builds on the correlation between biophysical properties and risk of cancer
occurrence.

Cancer cells are unlike healthy cells and can

be differentiated through a variety of
measurable properties. These properties
include deformability, rigidity, acoustical,
electrical, magnetic, nano-mechanical and
optical properties.

* Zacks_SCR_Research / October 20, 2020 John D. Vandermosten, CFA 16

Anpac Bio CDA - Advantages
Adopt "multi-level, multi-parameter"
The ability to detect early theory, ideas and methodology
Pre-cancer, Stage I

Cost effectiveness No harmful side-effects

Automated requiring
Early signal minimal human involvement

17
CDA Testing Process
Fully Automated Cancer Detection Device from Sample to Data Report AnPac Bio Sample Test Report

Heating and/or adding Multi-parameter detection at

reagent(s) (optional) various levels including at a
protein & cellular level

Sample
Sample Detection using
Blood Sample discharge and
preparation sensors
cleaning

Data transfer
and processing

CDA Cutoff Values

Low Risk: Below 42 CDA Value
Medium Risk: 42 to below 50 CDA Value
AnPac Bio cancer detection High Risk: 50 and above CDA Value
device

18
Meta-Analysis CDA Data on Various Types of Cancer*
Cerebral Cancer (93)
Nasopharyngeal Cancer (188) Sen.: 89.2%, Spec.: 89.9%
Sen.: 86.6%, Spec.: 89.1%
Lymphoma (528)
Esophageal Cancer (2,253) Sen.: 87.1%, Spec.: 92.4%
Sen.: 85.8%, Spec.: 93.0%
Gastric Cancer (1,438)
Lung Cancer (2,277) Sen.: 88.7%, Spec.: 93.8%
Sen.: 82.4%, Spec.: 83.0%
Colon Cancer (884)
Breast Cancer (493) Sen.: 89.4%, Spec.: 91.2%
Sen.: 74.6%, Spec.: 92.2%
Rectum Cancer (653)
Liver Cancer (804) Sen.: 89.2%, Spec.: 88.0%
Sen.: 92.3%, Spec.: 93.2%
Cervical Cancer (401)
Pancreatic Cancer (162) Sen.: 87.0%, Spec.:90.2%
Sen.: 89.3%, Spec.: 90.6%
Ovarian Cancer (474)
Prostatic Cancer (46) Sen.: 90.5%, Spec.: 90.1%
Sen.: 90.7%, Spec.: 93.2%
Uterine Cancer(164)
Sen.: 87.2%, Spec.: 92.3%
* As of December 31, 2019
Meta-analysis is a statistical analysis of a large collection of analysis results from individual studies for the purpose of integrating the findings. Sample size is indicated adjacent
to each cancer type in parenthesis.
19
Target Markets & Competitive Landscape
CDA Technology is applicable throughout the cancer management cycle.

• AnPac Bio’s CDA technology is a platform by which we can assess

the overall cancer risks for individuals combined with existing
bio-markers tests to identify where the cancer is most likely
Screening located at a competitive price point.
Assisting in
Diagnosis

• Cancer screening

Recurrence
Monitoring • Clinical validations are on going for cancer treatment prognosis
Prognosis |
Therapy Selection and follow-up

20
Prognosis & CDA in Long-Term Cancer Monitoring (Stage IIA Lung Cancer,
Follow-up Data of following through surgery and chemotherapy)

CDA Values
Variable
We tracked a number of PTF
CTF
patients throughout their 100
CDA

approximately three years of

cancer treatment.
The graph illustrates the

Value
changes of a representative
patient’s CDA values 50

throughout the tracking

period.

0 250 500 750

Time (days)

21
Retrospective Studies & Published Work

2015 ASCO Annual Meeting, J Clin Oncol 33, e12578,

2015 (co-author: Cancer Hospital of Chinese Academy of
Medical Sciences)

2015 Nobel Prize Laureate Summit on Biomedical

Sciences (co-authors: Shanghai Changhai Hospital and
School of Life Science of Fudan University)
2015 San Antonio Breast Cancer Symposium
(10.1200/JCO.2015.33.28_Suppl.13)
2017 ASCO Annual Meeting, J Clin Oncol 35, e23131,
2017 (co-authors: Shanghai Changhai Hospital and
School of Life Science of Fudan University)
2017 Gastrointestinal cancers Symposium (San
Francisco), J Clin Oncol 35, 2017 (suppl 4S; abstract 42)
2019 ASCO Annual Meeting, J Clin Oncol 37, e20673,
2019 (co-authors: Shanghai Changhai Hospital and Lishui
Central Hospital)
2019 Shenzhen New Horizons in Cancer Research

22
Summary
- Developed a novel cancer screening and detection technology with
• Significant patent protection, database and clinical studies
• Multiple performance and cost advantages
• On-going Class III medical device registration application (China), and
on-going LDT certification (US)

- Enjoyed significant growth in test volume, revenue and grows margin in

the last few years

23
Thank You
24